Decoding the Mechanism of Drugs of Heterocyclic Nature against Hepatocellular Carcinoma

Author(s):

Ayana R Kumar, Anitha L, Bhagyalakshmi Nair, Bijo Mathew, Sinoy Sugunan* and Lekshmi R. Nath*   Pages 882 - 893 ( 12 )

Abstract:

<P>Objectives: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and accounts for ~90% of cases, with an approximated incidence of >1 million cases by 2025. Currently, the backbone of HCC therapy is the oral multi-kinase inhibitor, Sorafenib, which consists of a Pyridine heterocycle ring system. This review highlights the introspective characteristics of seven anticancer drugs of heterocyclic nature against HCC along with their structural activity relationships and molecular targets. <P> Methods: Literature collection was performed using PubMed, Google Scholar, SCOPUS, and Cross ref. Additional information was taken from the official website of the FDA and GLOBOCAN. <P> Key findings/ Results: Based on the available literature, approved heterocyclic compounds show promising results against HCC, including Sorafenib (Pyridine), Regorafenib (Pyridine), Lenvatinib (Quinoline), Cabozantinib (Quinoline), Gemcitabine (Pyrimidine), 5-Fluorouracil (Pyrimidine)and Capecitabine (Pyrimidine), their mechanism of action and key aspects regarding its structural activity were included in the review. <P> Conclusion: Heterocyclic compounds represent almost two-thirds of the novel drugs approved by FDA between 2010 and 2020 against Cancer. This review summarizes the clinical relevance, mechanism of action, structural activity relationship, and challenges of the seven available anticancer drugs with heterocyclic ring systems against HCC.</P>

Keywords:

Heterocyclic compounds, hepatocellular carcinoma, structural activity relationship, gemcitabine, 5-Fluorouracil, sorafenib, cancer.

Affiliation:

Graphical Abstract:

Read Full-Text article